Can-Fite BioPharma Ltd.
Reinhold Cohn House
317 articles with Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. announced financial results for the three months ended March 31, 2019.
The Anti-NASH Effect of Namodenoson will be Presented at the International Conference on Fatty Liver in Berlin
Can-Fite BioPharma Ltd. announced that it has been selected for a podium presentation in a session of ‘Selected Abstracts of Excellence’ titled, “Namodenoson anti-NAFLD/NASH Activity is Mediated via De-regulation of the Wnt/β-catenin Pathway” at the 2nd Annual International Conference on Fatty Liver in Berlin, Germany which takes place on June 27-29, 2019.
Can-Fite’s Phase II Liver Cancer Data Selected for Presentation at a Leading Liver Cancer Scientific Forum (ILCA)
Can-Fite BioPharma Ltd. announced that the International Liver Cancer Association has accepted Can-Fite’s abstract describing the latest data from the Company’s Phase II Liver Cancer study of Namodenoson for an oral presentation at its annual conference.
Can-Fite Announces Preparation for End-of-Phase II Meeting with FDA to Initiate the Phase III Liver Cancer Study for Namodenoson
Fast Track and Orphan Drug Status; No treatment currently exists for advanced liver cancer patients in whom the current standard of care does not work
Can-Fite BioPharma Ltd. announced that the Company will change the ratio of its American Depositary Shares to ordinary shares from one ADS representing two ordinary shares to a new ratio of one ADS representing thirty ordinary shares.
Can-Fite Announces Late-Breaking Abstract Presentation on Namodenoson™ Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting
Acceptance for late breaking oral presentation underscores the oncology community’s interest in Namodenoson as a potential treatment for liver cancer
It has entered into a definitive agreement with certain institutional investors to receive gross proceeds of approximately $3.2 million.
Can-Fite BioPharma Ltd. announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2018 with the U.S. Securities and Exchange Commission.
Global distribution deals signed in Europe and China, including Can-Fite’s largest deal to date for up to $74.5 M
Can-Fite Announces Phase II Advanced Liver Cancer Top-Line Results for its Orphan/Fast Track Drug Namodenoson
Conference call with management scheduled for Tuesday March 26 at 8.30 a.m. Eastern time
Can-Fite has already entered into three partnership agreements in Asia providing for upfront payments and potential aggregate milestone payments of up to $85M for its drug candidates
Can-Fite BioPharma Ltd. announced the expansion of its distribution agreement with Chong Kun Dang Pharmaceuticals in South Korea, for the indication of non-alcoholic steatohepatitis.
Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal
Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a potentially fatal side effect of CAR-T and other immune-oncology therapies
Can-Fite BioPharma Ltd. announced that Pnina Fishman, Chief Executive Officer of Can-Fite Biopharma, has issued a Letter to Shareholders, the full text of which follows below.
Can-Fite BioPharma Ltd. today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $2.35 million.
Company filed patent application for the utilization of Namodenoson as an anti-obesity drug
Can-Fite to Participate in the Biotech Showcase™ 2019 and BIO One-on-One Partnering™@ JPM 2019 During the JP Morgan Healthcare Conference
A Phase II study of Namodenoson is enrolling patients for the treatment of NAFLD/NASH
Revenues for the Nine Months Ended September 30, 2018 Were $3.5 Million Compared to $0.7 Million for the Same Period in 2017
Data from Phase II study in advanced liver cancer are expected during Q1 2019
Due to Patient Survival, Top Line Results of the Namodenoson Phase II Advanced Liver Cancer Trial Expected Q1/19
Namodenoson seeks to address a major unmet need for Child Pugh B patients with advanced liver cancer